Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03958591
Other study ID # 2018YFC1314103
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date May 1, 2019
Est. completion date December 31, 2022

Study information

Verified date March 2022
Source Sun Yat-sen University
Contact Lijuan Xu, Dr
Phone 020-87755766
Email xulijuan@mail.sysu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Despite advances in diabetes management, many patients with type 2 diabetes in China fail to achieve optimal glycemic control. One of the possible reasons is associated with the delay in therapeutic decision making that lags behind glycemic rise. The investigators design this study and presume that using vildagliptin and metformin in combination with basal insulin as sequential treatment after intensive insulin therapy, might better modulate the dual islet hormone dysfunction than traditionally stepwise upgrading therapy pattern in patients with poorly controlled T2DM, and thus lead to a glucose normalization, β-cell function improvement and therapy simplification.


Description:

This is a multicenter, randomized, controlled, open-label, clinical superiority trial. The participants will be recruited from 19 centers in China. The enrolled participants will be randomly assigned into 3 groups, designated as Group A , B and C. Group A (Intensive therapy group following up with intelligent equipment):Continuous subcutaneous insulin infusion (CSII) will be applied to the participants for 2 weeks and thereafter the combination therapy of basal insulin, metformin and vildagliptin for the next 10 weeks. The participants are followed up with intelligent equipment. Group B (Intensive therapy group following up in traditional ways): CSII will be applied to the participants for 2 weeks and thereafter the combination therapy of basal insulin, metformin and vildagliptin for the next 10 weeks. The participants are followed up in traditional ways. Group C (Traditionally upgrading group): The participants will be applied the combination therapy of basal insulin, vildagliptin and metformin for the entire 12 weeks. Participants in both Group A, B and Group C will then receive combination therapy of metformin and vildagliptin, and be followed-up at the 16th, 20th, 24th, 28th, 32nd and 36th weeks. The doses of metformin and vildagliptin are set as 1.0~2.0g/d and 100mg/d, respectively. If the participants cannot tolerate metformin, then acarbose (50-100mg tid) or SGLT2 inhibitor can be instead used. If glucose is not well controlled, sulfonylureas or glinides can be added as a rescue treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 274
Est. completion date December 31, 2022
Est. primary completion date June 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Type 2 diabetes diagnosed according to WHO criteria (1999); With a duration of 1~10 years; 2. With two or more oral hypoglycemic drug used for at least 3 months, including at least one insulin secretagogue in half-max dosage (eg. Glibenclamide 7.5mg/d, gliclazide 60mg/d, glimepiride 3mg/d, glipizide 10mg/d, repaglinide 6mg/d, nateglinide 360mg/d and DPP-4 inhibitor with regular doses); 3. HbA1c of 7.5 to 13% and fasting C-peptide >0.4 nmol/L; 4. Age of 18 to 70 years; 5. BMI of 20 to 35 kg/m²; 6. Capable of and willing to follow doctors' instructions to: - Self-monitor blood glucose according to the protocol; - Follow the protocol and have regular visits as required; ? Record and maintain the research diary, as required by the protocol; ? Keep contact with the investigators and receive phone calls during the study. Exclusion Criteria: 1. Type 1 diabetes or specific types of diabetes; 2. Those who have received premixed insulin therapy and/or basal - meal insulin and/or basal insulin-oral hypoglycemic agents treatment accumulation for 7 days or more, and those who have received CSII therapy in the last one year, and those who have received GLP-1 analogue within 3 months before screening; 3. Those who have acute diabetic complications (diabetic ketoacidosis, hyperosmotic hyperglycemia coma or lactic acidosis); 4. Those who have severe diabetic microvascular complications (proliferative retinopathy, clinical proteinuria, and glomerular filtration rate less than 45 ml/min, uncontrolled diabetic neuropathy and obvious diabetic autonomic neuropathy); 5. Those with ALT >2.5 times of the upper limit of normal (ULN), bilirubin > 1.5 times of ULN; 6. Those with known macrovascular disease: Patients with acute cerebrovascular accident, acute coronary syndrome, unstable angina, peripheral artery disease who have received vascular intervention or amputation in the 12 months before enrollment; Or chronic cardiac dysfunction with cardiac function grade III or above; 7. Those with poor blood pressure control (systolic blood pressure=160mmHg and/or sitting diastolic blood pressure =110mmHg) and inability to control under 160/110mmhg within 1 week; 8. Serious systemic disease or malignant tumor, chronic diarrhea, etc; 9. Those with drugs that may affect blood glucose for a cumulative time of more than 1 week within 12 weeks, such as oral/venous glucocorticoid, growth hormone, estrogen/ progesterone, high-dose diuretics, antipsychotic drugs. However, low-dose diuretics for antihypertensive purposes (HCTZ < 25mg/d, indapamide < 1.5mg/d) and physiologic dose of thyroid hormone for replacement therapy are not included; 10. Any factors that may affect the participation of the subject in the study or the evaluation of the results; 11. Pregnancy or planned pregnancy, lactation subjects.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CSII and thereafter combination therapy, followed up with wearable devices
Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin; Wearable devices and smart apps will be used to manage and follow-up the participants.
CSII and thereafter combination therapy, followed up in traditional ways
Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin; Traditional ways such as telephone contact will be used for follow up.
Traditionally upgrading therapy, followed up in traditional ways
The participants will be applied the combination therapy of basal insulin, metformin and vildagliptin for the entire 12 weeks. Traditional ways will be used for follow up.

Locations

Country Name City State
China Department of endocrinology, FAH-SYSU Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Yanbing Li

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary the proportions of treatment simplification the proportions of patients who can maintain glycemic targets (HbA1c<7%) with only combination of oral hypoglycemic agents 24 weeks after the insulin treatment
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Not yet recruiting NCT06327711 - Benefits of Nutritional Ingredients for Type 2 Diabetes N/A
Recruiting NCT04164602 - The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly
Completed NCT05915338 - Training on Using ıInsulin in Patients With Type 2 Diabetes
Not yet recruiting NCT04998461 - Impact of Obesity, Chronic Kidney Disease and Type 2 Diabetes on Human Urinary Stem Cells
Not yet recruiting NCT04880005 - Digital Individualized and Collaborative Treatment of T2D in General Practice Based on Decision Aid N/A
Recruiting NCT05365529 - Time-Restricted Eating for Type II Diabetes: TRE-T2D N/A
Completed NCT05284071 - Actiste® Diabetes Management as a Service (ADMS) Clinical Investigation N/A
Recruiting NCT05501093 - Diabetes Reversal and the Subgingival Microbiota
Active, not recruiting NCT05784220 - The Canadian Diabetes Prevention Program N/A
Active, not recruiting NCT04286555 - Dietary Approaches to Stop Hypertension for Diabetes N/A
Completed NCT05076656 - Epigenetic and Microbiota Modifications Early Phase 1
Completed NCT04423302 - Effect of Totum-63 on Glucose and Lipid Homeostasis in Subjects With Dysglycemia (REVERSE-IT) N/A
Completed NCT05928637 - A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of D745, D759, and D150 Phase 1
Active, not recruiting NCT04660630 - A Real World Research: Comparison of Precision and Experience Therapy for Hypertension, Diabetes or Hyperlipidemias N/A
Recruiting NCT03435328 - Hyposalivation Response To Transcutaneous Electrical Nerve Stimulation In Diabetic Type 2 Patients N/A
Recruiting NCT04447859 - 16-week Flexible vs. 8-week Semaglutide Titration Phase 3
Not yet recruiting NCT03968354 - NASH and Type 2 Diabetes: Role of the Receptor Activator of Nuclear Factor-κB (RANK) and Its Ligand (RANKL)
Terminated NCT04819256 - Primary Care Based Integrated Community Care Team Intervention N/A
Recruiting NCT05629221 - Organisational Models Supported by Technology for the Management of Diabetic Disease and Its Complications in a Diabetic Clinic Setting. A Randomised Controlled Trial Targeting Type 2 Diabetes Individuals With Non-ideal Glycemic Values N/A